Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial

Br J Haematol. 2022 Feb;196(4):e33-e37. doi: 10.1111/bjh.17903. Epub 2021 Oct 11.

PADIMAC investigators:
Shirley D'Sa, Andres Virchis, Michael Quinn, Charles Crawley, Guy Pratt, Mark Cook

¹ University College London Hospitals NHS Foundation Trust, London, UK.
² Cancer Research UK & UCL Cancer Trials Centre, London, UK.
³ Leeds Teaching Hospitals NHS Trust, London, UK.
⁴ UCL Cancer Institute, London, UK.
⁵ Division of Cancer Sciences, University of Manchester, Manchester Cancer Research Centre, Manchester, UK.
⁶ St. Bartholomew's Hospital, London, UK.
⁷ Guy's and St. Thomas' Hospital NHS Foundation Trust, London, UK.
⁸ Kings College London Hospital, London, UK.
⁹ St George's Hospital, London, UK.
¹⁰ Royal United Hospital, Bath, UK.
¹¹ Belfast Trust, Belfast, UK.
¹² Leeds Cancer Centre and Leeds Institute of Clinical Trials Research, Leeds, UK.

No abstract available

Keywords: autologous stem cell transplantation; high dose therapy; multiple myeloma; myeloma therapy.

Publication types